Baidu
map
J CARDIOVASC COMPUT 润色咨询

Journal of Cardiovascular Computed Tomography

出版年份：暂无数据 年文章数：549 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：11.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2021-12-28 MS54455111222

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2021-12-27 小动量

    如果文章发表了未提供ORCIDID如何添加？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2020-03-12 zakarya ahmed

    11月发文章，等了很久结果3月份直接拒绝，共6个月。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2017-10-07 颜建龙

    审稿速度:1.0
    经验分享：投了病例报告命中率较高

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2017-07-18 chenyuming

    3分边缘，希望能维持稳定，略有上升也不错。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1104933, encodeId=35b011049337f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104934, encodeId=075a110493421, content=如果文章发表了未提供ORCIDID如何添加？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586438, encodeId=1ee35864389a, content=11月发文章，等了很久结果3月份直接拒绝，共6个月。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/942FEA70050EEAFBD4DCE2C1FC775E/100, createdBy=ebff2274493, createdName=zakarya ahmed, createdTime=Thu Mar 12 00:00:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547976, encodeId=74fc54e976dc, content=审稿速度:1.0<br>经验分享：投了病例报告命中率较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/3zf2VLDpaVsALmv27uaHpkqnHseibibqrCPHo4dsQvFTrk8JUzviaLnprUnmLD3WTV0rAqXlcZnxW8Gy7zAFBU9GQ/132, createdBy=c5971711971, createdName=颜建龙, createdTime=Sat Oct 07 08:51:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539487, encodeId=562a53948e27, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=281, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507737, encodeId=24f350e7379e, content=第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=369, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Wed Nov 19 21:29:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2014-11-19 匿名用户

    第一次投这个杂志，已投出去整整一个月，很忐忑，希望能接收！愿意和大家一块分享经验。

    0

共8条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map